Skip to content

Pipeline

Different biology.Different possibilities.

OP01 — NextGen leads the pipeline in Major Depressive Disorder. Behind it, Object Pharma is building a platform of differentiated neurotoxin opportunities.

Pipeline

One lead program.
A platform behind it.

Lead

OP01 — NextGen

Major Depressive Disorder

Mental & brain health

Preclinical

Platform

Selected neurotoxin development opportunities. Program details pending corporate approval.

OP02

Pending approval

Pending approval

Pending approval

OP03

Pending approval

Pending approval

Pending approval

Broader applications

Potential therapeutic and aesthetic applications arising from differentiated neurotoxin biology. Exploratory — not active clinical programs.

Future possibilities arising from Object Pharma's neurotoxin science and the ObNowa European platform — communicated as scientific optionality, not as disclosed development programs.

Publication discipline

Program nomenclature, molecules, indications, development stages, territories and Object / ObNowa relationships beyond OP01 are under corporate review. This page will be updated once program details are approved for publication.